Bicara Therapeutics (BCAX) Non-Current Assets (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Non-Current Assets of $8.7 million for Q1 2026, up 18.59% year-over-year from $7.3 million in Q1 2025, and down 2.87% quarter-over-quarter from $8.9 million in Q4 2025.
Bicara Therapeutics (BCAX) Non-Current Assets (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Non-Current Assets history runs 4 years deep, the most recent figure standing at $8.7 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 18.59% year-over-year to $8.7 million; the TTM figure through Mar 2026 stood at $154.1 million (up 657.28% YoY), while the FY2025 annual figure was $8.9 million, up 19.8% from the prior year.
- Non-Current Assets for Q1 2026 stood at $8.7 million, down from $8.9 million in the prior quarter.
- The five-year high for Non-Current Assets was $127.3 million in Q3 2025, with the low at $2.7 million in Q3 2024.
- The 4-year median for Non-Current Assets is $8.1 million (2024), against an average of $21.8 million.
- The sharpest annual moves came in 2025 and 2026: Non-Current Assets jumped 4688.12% in 2025, then increased 18.59% in 2026.
- Bicara Therapeutics' Non-Current Assets stood at $2.9 million in 2023, then surged by 156.55% to $7.5 million in 2024, then climbed by 19.8% to $8.9 million in 2025, then dropped by 2.87% to $8.7 million in 2026.
- Business Quant data shows BCAX's Non-Current Assets at $8.7 million in Q1 2026, $8.9 million in Q4 2025, and $127.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | 8.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.42 Mn |
| Mar 31, 2026 | 8.68 Mn |
| Dec 31, 2025 | 8.94 Mn |
| Sep 30, 2025 | 127.32 Mn |
| Jun 30, 2025 | 9.20 Mn |
| Mar 31, 2025 | 7.32 Mn |
| Dec 31, 2024 | 7.46 Mn |
| Sep 30, 2024 | 2.66 Mn |
| Dec 31, 2023 | 2.91 Mn |